A decade behind schedule, Shire finally gets an FDA OK for long-acting ADHD drug
It took a decade longer than Shire had originally bargained on, but the biotech has finally landed FDA approval of its long-acting ADHD drug SHP465 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
